Dr David Miklos, of Stanford University, reports on results of three of the most talked-about studies on CAR T-cell therapy in patients with large B-cell lymphoma (LBCL) as presented at this year’s American Society of Hematology annual meeting.
Dr Miklos begins with side-by-side comparisons of the trial schema and promising event-free survival outcomes of the ZUMA-7 and TRANSFORM studies.
He then offers his take on why study design differences led to positive outcomes for LBCL in the axi-cel and liso-cel arms of ZUMA-7 and TRANSFORM, respectively, but a negative outcome for patients with LBCL in the tisa-cel arm of the BELINDA study. All therapies targeted CD19, and all studies shared the aim of moving CAR T-cell therapies from standard-of-care third-line to second-line.
Finally, Dr Miklos discusses therapies that may receive FDA approval and changing approaches to salvage therapy for patients with relapsed and refractory LBCL.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Key Reports in Lymphoma CAR T Therapies From ASH 2021 - Medscape - Jan 06, 2022.
Comments